润都股份(002923) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company forecasts a net loss for the first half of 2025, with significant declines in net profit attributable to shareholders and non-recurring net profit Forecast Period This performance forecast covers the period from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[2] Performance Forecast Details The company expects a net loss for the first half of 2025, with both net profit attributable to shareholders and non-recurring net profit turning from profit to loss, and basic earnings per share also becoming a loss Key Financial Indicators for H1 2025 Performance Forecast | Item | Current Period Forecast (CNY 10,000) | Prior Period (CNY 10,000) | Year-over-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Loss: 3,000 – 3,900 | Profit: 3,780.15 | Decrease: 179.36% – 203.17% | | Net Profit After Deducting Non-recurring Gains and Losses | Loss: 3,800 – 4,600 | Profit: 3,147.86 | Decrease: 220.72% – 246.13% | | Basic Earnings Per Share (CNY/share) | Loss: 0.09 – 0.12 | Profit: 0.11 | - | Communication with Accounting Firm The company has pre-communicated with its accounting firm regarding the unaudited performance forecast data, with no significant disagreements identified Communication Results The current performance forecast data is unaudited, but the company has pre-communicated with the accounting firm, and both parties have no significant disagreements regarding the forecast - The financial data related to the performance forecast has not been audited by the accounting firm[3] - The company has pre-communicated with the accounting firm regarding the performance forecast, and there are no significant disagreements between the parties[3] Explanation of Performance Changes Performance decline is primarily due to pharmaceutical industry policies and market competition, leading to decreased sales volume and price for key preparations, significant gross margin reduction, and lower raw material drug prices Key Influencing Factors The performance decline is mainly attributed to pharmaceutical industry policies (national centralized procurement) and market competition, resulting in a significant drop in sales volume and price for key preparation products, a substantial decrease in gross profit, and a notable reduction in raw material drug product sales prices, collectively leading to a significant year-over-year decrease in operating revenue and profitability - Sales volume of Rabeprazole Sodium Enteric-coated Capsules, a key profitable preparation product, significantly decreased due to pharmaceutical industry policies, especially national centralized procurement, and market factors[4] - Sales volume and prices of other major preparation products were also affected to varying degrees, leading to a decline in gross margin[4] - Due to domestic and international market competition, sales prices of key raw material drug products significantly decreased, resulting in a year-over-year decline in operating revenue and product profitability[4] Risk Warning The company advises investors that the performance forecast data is preliminary, and final financial figures will be based on the officially disclosed H1 2025 report Investment Risk Disclosure The company reminds investors that this performance forecast data is a preliminary calculation result, and the final financial data will be subject to the officially disclosed 2025 semi-annual report; investors are advised to be aware of investment risks - The forecast data is preliminary, and specific financial data will be subject to the company's officially disclosed 2025 semi-annual report[6] - Investors are kindly reminded to be aware of investment risks[6]